The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review
Chilcott J, Wight J, Lloyd Jones M, Tappenden P
Record ID 32001000968
This review was performed to evaluate the use of pioglitazone in its licensed indication, in combination with metformin or sulphonylurea. For completeness, the review also considered its use in combination with insulin and as monotherapy (unlicensed indications).
Authors' recomendations: The evidence suggests that, compared with placebo, pioglitazone is effective in reducing blood glucose in patients with inadequate glycaemic control, both when used as monotherapy and in combination with existing licensed therapies. However, there is no firm evidence to indicate that pioglitazone is more effective than any other antidiabetic agent, particularly when used in combination. Additionally, it is unclear how pioglitazone therapy affects the incidence of microvascular and cardiovascular complications.
Authors' methods: Systematic review
Project Status: Completed
URL for project: http://www.hta.ac.uk/1192
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
- Blood Glucose
- Diabetes Mellitus
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: 2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.